Hydrophilic IOL yields low incidence of Nd:YAG capsulotomy
October 1st 2003New York-The 1-year follow-up of the Hydroview IOL (Bausch & Lomb) indicates that the lens is safe and provides excellent postoperative visual outcomes, a low incidence of Nd:YAG capsulotomy, and no cases of decentration, according to Douglas Grayson, MD, FACS.
Lighthouse symposium covers AMD, glaucoma
October 1st 2003New York-The North American Scientific Symposium on Age-Related Vision Impair-ment will focus on age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. The two-day conference at Lighthouse International's headquarters here Oct. 16 to 17 is presented by Lighthouse International, AMD Alliance International, and the Canadian National Institute for the Blind.
European study's interim results favorable for myopic PRL
September 15th 2003San Francisco-An interim analysis of data from an ongoing European multicenter study of the Phakic Refractive Lens (PRL, CIBA Vision/Medennium) indicates that the posterior chamber implant is a safe, effective, and predictable method for correcting high myopia, said Bo Philipson, MD, PhD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Silicone punctum plugs improve ocular surface in dry eye
September 15th 2003Fort Lauderdale, FL-Blocking the canaliculus with silicone punctal plugs has been shown to improve the stability of the tear film, decrease the ocular surface staining scores and squamous metaplasia grades, and increase the goblet cell density, according to Dilek Dursun, MD.
Amniotic membrane lowers chance of pterygium recurrence
September 15th 2003Jacksonville, FL-The chances of pterygium recurrence can be decreased substantially by removing the entire pterygium, not simply the head. In cases of extensive excision, amniotic membrane transplantation seems to provide excellent results, according to Arun Gulani, MD.
Understanding endpoints for quality of vision important
September 15th 2003Houston-Developing a basic understanding of the relationships among wavefront, contrast sensitivity, and Snellen visual acuity and how each describes quality of vision is critical to interpreting studies investigating the efficacy and safety of wavefront-guided refractive surgery, noted Jack T. Holladay, MD, MSEE, FACS.
Aberrometers provide useful source for refractive error data
September 15th 2003San Francisco-The integration of refractive error information obtained with a wavefront aberrometer into surgical planning may improve the results of conventional LASIK, said David R. Hardten, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Intraoperative pachymetry valuable for LASIK safety
September 15th 2003San Francisco-Intraoperative pachymetry is important in eyes undergoing LASIK because corneal thicknesses measured just before the microkeratome pass differ significantly from values obtained on a preoperative day, and at least when using the Hansatome microkeratome (Bausch & Lomb), correlate significantly with flap thickness, said Michael A. Redmond, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Wavefront aberrometry yields essential data for managing post-LASIK symptoms
September 15th 2003San Francisco-Wavefront aberrometry is a valuable tool for understanding the etiology of visual complaints post-LASIK in some patients with large pupils and appears to be promising as well for guiding "custom upgrade" procedures to address debilitating symptoms in those cases, said James J. Salz, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Flap creation safe with femtosecond laser
September 15th 2003San Francisco-Femtosecond laser technology (Intralase FS laser, IntraLase Corp.) provides LASIK surgeons a more precise, predictable method for creating a corneal flap than the conventional mechanical microkeratomes, explained two LASIK experts at the American Society of Cataract and Refractive Surgery annual meeting.
Scleral-corneal incision limits induced astigmatism
September 15th 2003Mesa, AZ-A one-pass scleral-corneal incision technique seems to "offer the best of both worlds" to cataract surgeons, according to Neal Nirenberg, MD, who uses the technique almost exclusively for his cataract patients in his private practice in Mesa, AZ.
Nidek sets wheels in motion to be GM of health care
September 15th 2003Hideo Ozawa has an aggressive vision for his company. As president and founder of Nidek Inc., Ozawa has set a plan in motion to transform the Japan-based eye-care company to the size of General Motors by the end of the 21st century.
Combined procedure used to treat Graves' orbitopathy
September 1st 2003Kansas City, MO-The combination of endoscopic medial wall and floor and transcutaneous lateral orbital decompression used to treat Graves' orbitopathy has a low risk of morbidity, but may not result in as much anatomic retropulsion of the globe as other methods, according to W. Abraham White, a medical student at the University of Missouri-Kansas, Kansas City, MO. White presented an analysis of results achieved by one otolaryngologist and one ophthalmologist using this method.
Initial tests of laser treatment for presbyopia are promising
September 1st 2003n]1?4?Id of small studies conducted in the United States and Canada found that most patients who underwent laser presbyopia reversal (LAPR) had significant clinical improvement and could read magazines and newspapers without glasses shortly after surgery.
Steroid is safe for treating conjunctivitis
September 1st 2003Loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb Pharmaceuticals and Pharmos Corp.), the so-called "safe steroid" approved for treatment of seasonal allergic conjunctivitis, appears to be living up to its billing, according to several ophthalmologists who prescribe the drug for a range of ophthalmic allergies.
Cyclosporine drops useful in topical steroid-resistant eyes
September 1st 2003Fort Lauderdale, FL-Cyclosporine A drops may be an effective treatment for Thygeson's superficial punctate keratitis (SPK) over the long term. It is especially useful in patients whose disease does not respond to treatment with steroids or those whose disease responds to steroids and who have elevated IOP levels, according to the results of a U.K. study reported at the Association for Research in Vision and Ophthalmology.
Patient compliance improves with twice-daily dosing
September 1st 2003Fort Lauderdale, FL-A twice-daily dosing regimen of pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., of Napa, CA, and Tampere, Finland) is as effective as the four-times-daily regimen of the drug for treating seasonal allergic conjunctivitis. The simpler dosing regimen may enhance patient compliance.